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Abstract 
 
CHARLOTTE SHATTEN: Examination of Balance Using Laboratory-Based and Clinical 
Measures in Female Survivors of Breast Cancer 
 (Under the direction of Dr. Claudio Battaglini) 
 
 This study compared laboratory-based and clinical measures of balance between 10 
breast cancer survivors (BCS) and 10 healthy, age, weight, and physical activity level 
matched controls (CNT). The single leg stance (SLS) and force plate parameters (sway speed 
(SS) and sway path (SP)) were the main outcome variables.  No statistically significant 
differences were found on the clinical SLS with either eyes open or closed between the BCS 
and CNT groups (p=0.38, p=0.37; respectively).  Additionally, no significant differences 
between groups were found on the laboratory-based measures SS or SP during any test 
condition (p≥0.05). In conclusion, no significant differences in balance using either clinical 
or laboratory-based tests between BCS and CNT were observed in this study.  It appears that 
the age differences in BCS enrolled in this study compared to other studies and the amount of 
time off cancer therapy, may explain in part the non-significant differences between groups.  
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Chapter I 
Introduction 
After skin cancer, breast cancer is the most frequently diagnosed cancer in women.  
In 2011, it was estimated that 288,130 women were diagnosed with breast cancer; of those 
approximately 248,810 women were expected to survive (American Cancer Society: Breast 
Cancer Facts and Figures 2011-2012., 2011). Breast cancer is the second leading cause of 
cancer death in women; nonetheless the mortality rates for women with breast cancer have 
been steadily declining since 1990 (American Cancer Society: Breast Cancer Facts and 
Figures 2011-2012., 2011).  Advances in diagnosing technology and improved treatment 
have rendered most types of breast cancer successfully treatable, with survival rates as high 
as 90% (American Cancer Society: Breast Cancer Facts and Figures 2011-2012., 2011).  
The high survival rates for breast cancer leave a large population of women coping with 
psychological and physiological side effects from the diagnosis of the disease and the harsh 
nature of its treatment.  Chemotherapy is often used in conjunction with radiation and 
potentially surgery to eradicate breast cancer cells.   Commonly observed side effects of 
treatment include: reduced cardiorespiratory fitness, reduced muscle strength, increased 
fatigue (Courneya & Friedenreich, 1999), depression, peripheral neuropathy, vestibular 
damage, and vision changes (Hile, Fitzgerald, & Studenski, 2010; Scaioli et al., 2006; 
Verstappen et al., 2005; Zhang, Liu, Ding, & Salvi, 2003).  Some side effects reported in the 
oncology literature and by breast cancer survivors are receiving more attention among the 
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medical community due to their impact on the overall functionality, health, and quality of life 
of survivors; one such side effect is a decreased ability to balance.  Survivors anecdotally 
report that they are finding themselves using walls and railings during ambulation to help 
maintain their balance and that tripping more frequently has become a regular occurrence 
while attempting to perform their regular activities of daily living. 
The mechanism for balance decline in breast cancer survivors is understudied; 
however, it is known that chemotherapeutic agents can be taxing to physiological systems 
that are important for the maintenance of balance (Griffin & Garnick, 1981; Sergi, Ferraresi, 
Troiani, Paludetti, & Fetoni, 2003; Wampler et al., 2007).  Balance requires integrated input 
from the somatosensory, visual, and vestibular systems; loss of one system’s input increases 
reliance on the input from another system.  These systems provide redundant feedback in 
order to allow for corrective torque from the muscles to stabilize posture (Peterka & 
Loughlin, 2004).  Healthy, young populations correct for small perturbations in balance by 
swaying about the ankles; muscles activate from the ankles toward the core, an ankle 
strategy.  In older populations, perturbations in balance cause posterior hip displacement and 
anterior chest or torso displacement, a hip strategy (Manchester, Woollacott, Zederbauer-
Hylton, & Marin, 1989).  The hip strategy is seen mostly in populations that have deficit in 
their ankle strategy; those with injury or neuropathy often employ hip strategy in response to 
displacements that healthy populations would employ ankle strategy (Horak, Nashner, & 
Diener, 1990a; Winters-Stone et al., 2011).  In breast cancer survivors, due to the nature of 
anti-cancer treatment, physiological systems involved during maintenance of balance can be 
disrupted.  Some theories have been postulated as to why balance issues may be occurring in 
this population (Wampler et al., 2007; Winters-Stone et al., 2011).  
	  	   3	  
Neuropathic pain occurs as a side effect of treatment by taxane in more than 50% of 
women (Jung, Herrmann, Griggs, Oaklander, & Dworkin, 2005).  The duration and extent of 
chemotherapy induced peripheral neuropathy (CIPN) is unclear, but is believed to impact 
balance and other physical abilities that can negatively impact the quality of life of cancer 
survivors.  Damage to the nerves in the feet and ankles commonly associated with taxane 
therapy can cause decreased proprioceptive sense.  Proprioception allows the brain to 
determine where the body is in relation to a surface and in relation to other parts of the body 
through the somatosensory system (van Deursen & Simoneau, 1999).  Proprioception is 
important not only for balance, but also as a protective mechanism upon painful sensory 
stimulation.  Women who experience changes in proprioceptive input could be more likely to 
have decreased ability to maintain balance.  CIPN can inhibit proprioceptive information in 
ways similar to diabetic peripheral neuropathy.  In people with diabetic peripheral 
neuropathy, significant balance instability is a common occurrence, as well as an abnormal 
shift from ankle to hip strategy to maintain proper balance (Horak, Nashner, & Diener, 
1990b; Simmons, Richardson, & Pozos, 1997b).  Decreased input from proprioception 
causes increased reliance on the vestibular and visual systems for the maintenance of 
balance. 
The vestibular system provides information on body orientation and movement.  
Recent data have shown that vestibular deficit is present in breast cancer survivors, and that 
this is a positive predictor of a fall in this population (Winters-Stone et al., 2011).  Age 
related degeneration of the vestibular and visual systems is common, (Rauch, Velazquez-
Villaseñor, Dimitri, & Merchant, 2001).  The potential impact of anti-cancer treatment, could 
be a cause of reduced ability to balance in older survivors of breast cancer.  
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Speculations regarding negative changes in body composition associated with loss of 
muscular mass with concurrent gain in fat mass (a condition called sarcopenic obesity) is a 
possible cause of decreased balance in cancer survivors.  The musculoskeletal system is the 
system responsible for locomotion, and is directly associated with the ability of humans to 
balance.  However, one previous study that examined decreases in strength as a cause of 
decreased balance failed to confirm this possibility (Tysinger, 2010).  No significant 
differences when balance was measured through clinical variables (SLS, four square step 
test, and 360° turn) were observed between a group of breast cancer survivors and a control 
group matched on age and fitness level.  The authors suggested that breast cancer survivors, 
who had completed their major treatments within 6 months, were functional enough to be 
able to perform physical tasks similarly to their counterparts of similar fitness level, and that 
the non-significant balance differences could be attributed to the lack of sensitivity of the 
clinical measures used for the assessment of balance (single leg stance, 360 degree turn, and 
the four square step test for the assessment of static and dynamic balance) (Tysinger, 2010).  
Only two studies have examined balance issues in breast cancer survivors using 
laboratory-based measurements, and both confirmed that balance is compromised (Wampler 
et al., 2007; Winters-Stone et al., 2011).  One unpublished study found no difference between 
breast cancer survivors and apparently healthy controls (Tysinger, 2010).  Therefore, the use 
of clinical versus laboratory-based measurements for the assessment of balance in cancer 
survivor must be evaluated.  This will enable clinicians to identify appropriate tools so that 
this understudied and undesirable side effect can be properly diagnosed and treated.  
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Statement of the Purpose 
The purpose of this study was to compare clinical and laboratory-based measures of 
balance between early stage breast cancer survivors and apparently healthy, sedentary age-
matched controls.  Exploratory analyses evaluating balance using the NeuroCom Sensory 
Organization Test in both breast cancer survivors and controls were performed as an attempt 
to identify potential explanations of balance disruption.  
Research Questions (R) 
R1.  Is there a difference in number of seconds that breast cancer survivors (BCS) and 
apparently healthy, age and weight matched controls (CNT) can perform a clinical single leg 
stance (SLS) with the eyes open?  
R2.  Is there a difference in the number of seconds that BCS and CNT can perform a clinical 
SLS with the eyes closed? 
R3.  Is there a difference in the sway speed (centimeters/second) between BCS and CNT 
during a SLS on a force plate with the eyes open? 
R4.  Is there a difference in the sway speed between BCS and CNT during a SLS on a force 
plate with the eyes closed? 
R5.  Is there a difference in the sway path (cm) between BCS and CNT during a SLS on a 
force plate with the eyes open? 
R6.  Is there a difference in the sway path between BCS and CNT during a SLS on a force 
plate with the eyes closed? 
	  	   6	  
Hypotheses (H)  
H1.  There will be no significant difference in the number of seconds that the clinical single 
leg stance is performed between BCS and CNT with eyes open. 
H2.  There will be no significant difference in the number of seconds that the clinical single 
leg stance is performed between BCS and CNT with eyes closed.   
H3.  The CNT group will have a slower sway speed when compared to the BCS group with 
eyes open during the single leg stance when sway speed is measured in centimeters/second 
(cm/s) through the force plate.  
H4.  The CNT group will have a slower sway speed when compared to the BCS group with 
eyes closed during the single leg stance when sway speed is measured in centimeters/second 
(cm/s) through the force plate. 
H5. The CNT group will have a smaller sway path when compared to the BCS group during 
the single leg stance with eyes open when the center of pressure is measured in centimeters 
through the force plate. 
H6. The CNT group will have a smaller sway path when compared to the BCS group during 
the single leg stance with eyes closed when the center of pressure is measured in centimeters 
through the force plate. 
Definition of Terms 
Get REAL and HEEL Breast Cancer Research Program: A breast cancer rehabilitation 
program designed for Stage I-III breast cancer survivors.  Participants undergo exercise and 
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recreational therapy 3 times per week for 5 months.  Eligible participants have completed 
their planned anti-cancer therapy (including chemotherapy, radiation therapy, and surgery) 
within the prior six months and may currently be receiving adjuvant therapy (“Get REAL and 
Heel: An After Care Breast Cancer Program,” 2009). 
Breast Cancer Survivors: A group women treated for breast cancer who have completed their 
major therapy (chemotherapy, radiation therapy, or combination of these treatments) within 6 
months and could be undergoing adjuvant therapy at the time of data collection. 
Clinical Measures of Balance: Measures that are easily used in clinics, require few materials, 
and little specific training.  They can be easily conducted in a short amount of time and can 
provide basic information on balance performance. Performance information is usually 
assessed by how long the subject can complete the task, or by how long it takes the subject to 
complete the task. Included in these measures is the timed single leg stance.   
Laboratory-Based Measures of Balance: Measures that are likely to be used in laboratories, 
require specific training for use, and are typically costly.  Often, these measures provide 
specialized information on balance and sensory input; included in these measures are force 
plate assessments.   
Center of Pressure: the point of application of force between the feet and the force platform 
(van Schie, 2008). 
Sway Path: a quantification of postural stability from information provided by measurement 
of the center of pressure; reflects stability of stance.  The larger the signal the less stable the 
individual being tested (van Schie, 2008). 
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Sway Speed: a kinematic term often estimated from center-of-pressure measures derived 
from force plate data; the speed of center of pressure displacement is related to increased 
instability (Peterka & Loughlin, 2004; Winter, Patla, Prince, Ishac, & Gielo-Perczak, 1998).  
Static Balance: The ability to control the body while in a stationary position (Thibodeau & 
Patton, 1996).  
Peripheral Neuropathy:  Decreased sensation and proprioception, particularly on the plantar 
surface of the feet, ankles, and lower legs.  Peripheral neuropathy can cause feelings of 
instability, increased falls, and increased risk of foot injury (van Deursen & Simoneau, 
1999). 
Vestibular System: A compilation of organs in the inner ear.  Receptors called maculae, 
which contain hair cells, are located in the saccule and utricle in the inner ear and are critical 
for regulation of static balance.  During dynamic balance tasks, crista ampullaris within the 
semicircular ducts respond to angular or rotary movement.  The vestibular system initiates 
responses that fix the eyes on objects and activate muscles to maintain balance in response to 
acceleration and direction changes (Marieb & Hoehn, 2007).  
NeuroCom Sensory Organization Test: A static balance assessment with 6 conditions.  
During the six conditions sensory information is altered or inhibited through sway referenced 
movement of the force platform or visual surround to provide a quantitative analysis of 
sensory input to maintain balance (“Sensory Organization Test,” 2011).  
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Limitations 
1.  Anti-cancer treatment differences (based on cancer stage, treatment type, and duration of 
treatment) within the BCS group could cause differences within the measurement of 
variables in this study.  
2. All subjects in the BCS group will completed their major treatments within 6 months, but 
those who have completed treatment more recently may be experiencing more severe 
treatment related side-effects.  
3.  The minimum sampling time for the force plate is about 10 seconds; many breast cancer 
survivors may not reach this.  
Delimitations                                                                                                                             
1.  All subjects in the BCS group were participants in the Get REAL and HEEL Breast 
Cancer Program and were recruited via hospitals and clinics around the triangle and through 
the Great REAL and HEEL web page. 
2.  All subjects in the BCS group were diagnosed with stage I, II, or III breast cancer and had 
completed their major therapy within the preceding six months.  
3.  All patients in the BCS group had undergone chemotherapy and/or radiation as part of 
their major treatment plan. 
Significance of the Study 
Balance deficits in breast cancer survivors appear to be a quality of life and safety 
issue.  Studies examining this issue are scarce; currently, only three studies have examined 
the issue of balance deficits in breast cancer survivors (Tysinger, 2010; Wampler et al., 2007; 
Winters-Stone et al., 2011).  Results of these studies suggest that breast cancer survivors 
have balance deficits when measured by laboratory-based measures (Wampler et al., 2007; 
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Winters-Stone et al., 2011).  The only study using clinical measures showed no difference in 
balance between BCS and CNT (Tysinger, 2010).  Sensitivity issues associated with the 
clinical measurements used may have been the cause of non-significant difference in balance 
between BCS and CNT.  The latter study indicates the importance of evaluating the 
sensitivity of clinical measurements so clinicians can used them confidently when diagnosing 
balance deficits in breast cancer survivors.  Balance changes in breast cancer survivors after 
completion of major therapy appears to be an important issue that has been understudied.  
This study will add to the current knowledge regarding this potential issue.  This will allow 
for more effective evaluation of balance and if balance is a problem in breast cancer 
survivors, this study will aid in the development of interventions specifically designed to 
address this issue in this population. 
	  	  
Chapter II 
Review of Literature 
Introduction 
The American Cancer Society estimated, that about 248,810 women became 
survivors of breast cancer in 2011 (American Cancer Society: Breast Cancer Facts and 
Figures 2011-2012., 2011).  Many of these survivors have undergone various types of 
treatments and are coping with the associated side effects.  In the following review of 
literature: a brief description of side effects related to anti-cancer treatment, treatment related 
decreases in balance, laboratory-based and clinical measures of balance, and the implications 
that decreased balance may have on the quality of life of breast cancer survivors will be 
provided. 
Breast Cancer Treatment And Its Side Effects 
Cancer treatment is typically a combination of surgery, radiation, chemotherapy, and 
adjuvant therapy.  Adjuvant therapy occurs after surgery and consists of long-term, 
preventative drugs, and/or chemotherapy, and/or hormonal therapy when no detected cancer 
is left in the body.  Each treatment option has different risks and benefits depending on 
adjuvant therapy type, duration, and patient response
Surgery is an important component to breast cancer treatment.  Surgery involves 
removal of the part or all of the tumor and often removal of surrounding lymphnodes.  
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Surgery can range from removal of only the tumor (lumpectomy) to removal of the entire 
breast, all surrounding lymphnodes, and part of the muscles of the chest wall below the 
breast (radical mastectomy).  This is dependent on the tumor size and extent of lymphnode 
involvement.  Often following surgery, chemotherapy and/or radiation therapy are given to 
ensure that all tumor cells are eradicated (“Breast Cancer Treatment Physician Data Query,” 
2011). 
Radiation therapy involves treatment with high-energy ray or some other radioactive 
substance to eradicate cancer cells in a localized region.  Radiation can be through an 
external beam, or through brachytherapy.  External beam radiation often involves x-rays 
aimed externally at the area around the tumor or tumor site.  Brachytherapy involves small 
pellets of radioactive material placed directly into the breast tissue near the tumor.  Radiation 
treatment, duration, and intensity are dependent on the tumor stage and the extent of 
lymphnode involvement.  Radiation therapy is often given after breast conserving surgery to 
ensure that cancer cells are eliminated (“Breast Cancer Treatment Physician Data Query,” 
2011). 
In addition to radiation therapy, hormone therapy is an alternate type of adjuvant 
therapy.  Hormone therapy is available to women with hormone sensitive tumors as some 
tumors rely on estrogen to grow.  Hormone therapy stops hormone production or blocks 
hormone action to stop tumor growth.  Treatment with the drug tamoxifen blocks the action 
of estrogen on the breast tissue in pre-menopausal women.  Instead of blocking estrogen’s 
action, aromatase inhibitors decrease the body’s estrogen production and therefore prevent 
the growth of estrogen dependent tumors.  Aromatase inhibitors are given to post-
menopausal women who have hormone dependent breast cancer.  An alternate way to stop 
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estrogen production is by ovarian ablation, which stops the ovaries from functioning.  
Ovarian ablation can cause a women to go through menopause prematurely and can allow for 
other hormonal therapies to be more effective (“Breast Cancer Treatment Physician Data 
Query,” 2011).   
Chemotherapy is available in many different forms and with various different dosing 
protocols.  Chemotherapy can be given as either adjuvant therapy, after surgery, or neo-
adjuvant therapy to shrink the tumor before surgery.  Unlike radiation therapy, chemotherapy 
is a systemic treatment and is given either through a pill, intravenously, or through the 
cerebrospinal fluid.  Chemotherapy protocols and treatment plans are based on the tumor 
type, tumor location, and lymphnode involvement (“Breast Cancer Treatment Physician Data 
Query,” 2011).  Chemotherapy has evolved over the past 40 years; achievements in 
technology and the ability to assess biomarkers in cancer has improved breast cancer 
outcomes by 15-20% (Swain, 2011).  Physicians now have the ability to assess patient 
tumors and design chemotherapy regimens based on tumor receptors.  The ability to provide 
targeted chemotherapy based on tumor receptor type and menopausal status has helped to 
increase efficacy of cancer treatment (Nurgalieva et al., 2010).  
Chemotherapy is given based on the type of cancer, the genetics of the patient, other 
chronic illness, and concurrent medication use (“Breast Cancer Treatment Physician Data 
Query,” 2011).  For many women who need to receive chemotherapy, anthracyclines are the 
typical “first line” for the treatment of breast cancer.  Anthracyclines are often given in 
combination with cyclophosphamide (AC).  A few of side effects of AC therapy are as 
follows:  myelosuppression, nausea, vomiting, weight loss, hepatotoxicity, and cardiotoxicity 
(“Breast Cancer Treatment Physician Data Query,” 2011).  Other chemotherapy regimens 
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that are given for adjuvant treatment are combination, cyclophosphamide, methotrexate, 
flouracil or cyclophosphamide and doxorubicin, and taxane/cyclophosphamide  (Muss et al., 
2009).  Each regimen has its own battery of side effects as well as potential benefits that 
surpass the scope of this study. However, common chemotherapeutics for the treatment of 
breast cancer are outlined in Table 1. 
Table 1. Common Chemotherapeutics for the Treatment of Breast Cancer and Associated 
Side Effects: Some of These Could Negatively Affect Balance.   
Chemotherapeutic Side Effects Potential Effect on 
Balance 
Anthracyclines Cardiotoxicity n/a 
Taxanes Peripheral neuropathy 
(Argyriou et al., 2005; 
Hile et al., 2010; 
Nurgalieva et al., 2010) 
Decreased 
somatosensory feedback 
5-Flouroucil, corticosteroids, 
tamoxifen, 
cyclophosphamide, taxane 
Vision changes (Griffin 
& Garnick, 1981) 
Decreased visual 
information 
Cisplatin Vestibular damage (Sergi 
et al., 2003) 
Decreased vestibular 
reference information 
Aromatase inhibitors Bone loss (Mincey et al., 
2006) 
n/a 
The drug class, taxane, comes in two active forms, docetaxel and paclitaxel.  
Paclitaxel comes from the bark of the Pacific yew tree and has a higher risk of neuropathy 
when compared to its counterpart docetaxel, which is semi-synthetic (Hagiwara & Sunada, 
2004; Wickham, 2007).  According to Swain (2011), the addition of taxane therapy is 
beneficial to most women who have been diagnosed with breast cancer.  The addition of 
docetaxel to routine adjuvant chemotherapy treatment has improved outcome and quality of 
life for many women, in addition to limiting other adverse effects of combination therapy 
(Martin et al., 2005).  In a multi-center prospective study, it was found that the addition of 
docetaxel to doxorubicin and cyclophosphamide (TAC) was superior to combination 
flouracil, doxorubicin, and cyclophosphamide (FAC).  Event free survival after 5 years was 
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75% for the TAC group compared to 68% in the FAC group.  Additionally, TAC reduced the 
risk of recurrence by 39% and 17% in women with either three or four positive lymphnodes 
respectively.  Toxicity was higher in the TAC group, with the most common toxic side being 
neutropenia (Martin et al., 2005).  Although it appears that the risks of toxic side effects are 
increased, the addition of docetaxel seems to increase the rates of event free survival in 
women with lymphnode positive breast cancer.  
Peripheral neuropathy is a common side effect that is caused by taxane therapy can be 
attributed to microtubule aggregation in the distal nerves of the feet and hands.  Microtubules 
allow for intracellular transport, cell division, and structural support; aggregation inhibits 
these vital functions and causes demyelination and slowed nerve conduction.  As smaller 
distal nerves demyelinate and loose their nutrient supply, numbness, paresthesias, and 
burning occur often starting at the toes and plantar surface of the feet (Hagiwara & Sunada, 
2004).    
A well-documented side effect of taxane therapy is peripheral neuropathy.  In a study 
by Argyriou et al. (2005) 21 adults being treated with paclitaxel 66.6% presented with signs 
and symptoms of neuropathy after treatment of 175 mg/m2 per dose.  The neuropathy started 
in the lower limbs and progressed to the upper limbs (Argyriou et al., 2005).  This is 
consistent with other studies which found that patients treated with a platinum-taxane 
combination therapy were twice as likely to develop peripheral neuropathy (Nurgalieva et al., 
2010).  A case report by Hile et al. (2010) outlined the disability implications of paclitaxel 
induced peripheral neuropathy.  During the adjuvant treatment of breast cancer, an elderly 
woman experienced limiting peripheral neuropathy in her hands and feet after 3 cycles of 
paclitaxel (dose not reported) (Hile et al., 2010).  The neuropathy was still present 2.5 years 
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after cessation of therapy; the patient reported falls, cane use, and mobility- related disability 
(Hile et al., 2010).   
In addition to taxane induced peripheral neuropathy, chemotherapeutics can also 
damage other systems that are directly related to the maintenance of balance (Table 1). 
Vision changes associated with chemotherapy can cause postural control disturbances.  No 
studies were found on the relationship between breast cancer, vision and chemotherapy 
treatment.  A review by Griffin and Garnick (1981) outlines many chemotherapeutics and the 
changes to the visual system that occur as side effects.  This review includes common 
chemotherapeutics used during the treatment of breast cancer including: 5-flourouracil, 
corticosteroids, tamoxifen, and cyclophosphamide, and their effects on vision during and 
after infusion (Griffin & Garnick, 1981).  In a study of paclitaxel treated patients (n=32), 15 
patients showed visual electrophysiological changes during paclitaxel treatment. Fourteen 
patients displayed positive clinical/electrophysiological correlations; although there were no 
positive correlations between positive spontaneous visual symptoms and the chemotherapy 
treatment (due to occurrence in both groups).  This study suggests that the visual changes 
induced by paclitaxel could be due to optic nerve changes or vasculature changes to the 
retina (Scaioli et al., 2006).  Tan and Walsh (1998) also documented paclitaxel ocular 
toxicity in a brief report.  Two male patients were treated with paclitaxel for squamous cell 
lung cancer complained of blurred vision, light flashes, and numbness during infusion.  
Symptoms in both patients resolved within an hour after infusion; this was attributed to 
vasospasticity (Tan & Walsh, 1998).  In children (n=5) being treated with cyclophosphamide, 
blurring of vision occurred; this symptom lasted no more than 14 days and normal vision was 
restored (Kende, Sirkin, Thomas, & Freeman, 1979).  Vision changes experienced by 
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patients undergoing chemotherapy seem to be fleeting; however, poor visual acuity is 
associated with diminished postural control. Occlusion of the peripheral visual field 
increased postural sway in older adults (n=16) (Manchester et al., 1989).  Decreased foveal 
visual feedback alone resulted in diminished postural stability (Manchester et al., 1989). 
Vestibular damage caused by cisplatin therapy has been documented in animal 
studies.  Eight guinea pigs were injected with cisplatin for 6 days; a significant decrease in 
the vestibular-ocular reflex was found at the end of treatment along with a decrease in hair 
cells in both the cristae and utricular maculae (P > 0.625 & P > 0.907 respectively) (Sergi et 
al., 2003).  In relation to breast cancer survivors, Winters-Stone et. al. (2011) found that 
women had decreased vestibular input during the Neurocom SOT.  This finding could 
suggest changes to the vestibular system caused by cancer treatment (Winters-Stone et al., 
2011).  
Anti-Cancer Treatment Side Effects Potentially Associated with Decreased Balance in 
Breast Cancer Survivors 
Balance changes in female breast cancer survivors were first explored by Wampler et 
al. (2007).  Upon examination of 20 breast cancer patients treated with taxane therapy, the 
breast cancer group had decreased balance outcomes as assessed by the NeuroCom SOT 
when compared to healthy, matched controls (Wampler et al., 2007).  The women who had 
been treated with taxane therapy performed more poorly on both measures when compared 
with healthy controls (Wampler et al., 2007).  
Recently, Winters-Stone et al. (2011) found that a group of post-menopausal breast 
cancer survivors had decreased vestibular input during balance testing with the NeuroCom 
SOT, which led to an increased fall risk.  This study assessed 59 women with stage I-III 
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breast cancer; 76% of their study population experienced a fall from a year prior to study 
enrollment to 6 months thereafter (Winters-Stone et al., 2011).  In addition to measuring 
balance with the SOT, they assessed: gait speed, maximal lower limb strength, functional 
lower body strength, muscular power testing, muscle mass, visual acuity, spatial contrast 
sensitivity and self reported fall history.  Subjects who took longer to read letters on the 
contrast sensitivity chart were more likely to have a history of falls.  Interestingly, the 
vestibular portion of the SOT was the only mediator of the relationship between treatment 
and falls.  All past- fallers had lower scores on condition 5 of the SOT, which attributed to 
lower vestibular scores, but having a low vestibular score could not predict future falls.  
Furthermore, the chemotherapy only group was more likely to have experienced a fall than 
the chemotherapy plus endocrine therapy group, or the endocrine therapy only group.  This 
study suggests that changes to the vestibular system could be caused by cancer treatment 
(Winters-Stone et al., 2011).  Effective maintenance of balance requires sensory input from 
the visual, vestibular, and somatosensory systems.  Altered or inhibited input from any of 
these systems could have a negative impact on balance. 
Sensory Input for Balance Control 
In diabetic populations, the presence of neuropathy (DPN) is regarded as the key 
factor in loss of independence and as having a major impact on quality of life (van Schie, 
2008).  Peripheral neuropathy also impacts postural control in diabetics (Lafond, Duarte, & 
Prince, 2004; van Deursen & Simoneau, 1999; van Schie, 2008).  In a study of 11 elderly 
patients with type 2 diabetes mellitus and 20 healthy elderly individuals, patients with 
diabetic neuropathy had greater hip and ankle control mechanisms and an increased deviation 
from their center of pressure in the eyes open and eyes closed trials (Lafond et al., 2004).  
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This indicates that patients with DPN had poorer standing postural control than their healthy 
elderly counterparts.  One limitation to most studies assessing peripheral neuropathy is the 
difficulty in quantifying the severity of the neuropathy.  Severity of DPN depends on the 
degree of neuropathy and the size fibers that are affected; the smaller the afferent fiber 
affected, the more severe the balance deficit (Nardone, Galante, Pareyson, & Schieppati, 
2007).  In a study of sensory neuron disease (SND) (n=11), it was found that patients with 
SND had greater sway areas; and were limited similarly in sensation, but had fewer motor 
deficits than those with DPN (n=14) (Nardone et al., 2007).  
Horak et al. (1990) preformed a within subjects experimental study to obtain 
information pertaining to neuropathy and decreased postural control caused by ischemia.  
They found that during the ischemic trail, muscle activation pattern changed favoring the use 
of a hip strategy to maintain upright balance during the SOT.  The muscles used to maintain 
balance changed based on the amount of hip displacement used to illicit a postural change 
response; all 6 subjects showed increased use of the hip strategy during the somatosensory 
loss trial (Horak, Nashner, & Diener, 1990a).  After extensive PubMed search, no studies 
were found indicating the use of a hip strategy or an ankle strategy in any cancer population.   
Nashner et al. (1982) found that the vestibular system has two important roles in 
postural control inputs: first, when combined with inputs from the visual and somatosensory 
system the vestibular system helps to maintain equilibrium control.  Second, the vestibular 
system provides orientation reference which conflicts the information given by the visual and 
somatosensory system.  Patients with vestibular deficit were unable to suppress the influence 
from the visual and proprioceptive inputs; vestibular loss caused inappropriate responses to 
	  	   21	  
visual and proprioceptive stimuli which elicited postural stability disturbances (n=12) 
(Nashner, Black, & Wall, 1982).  
Laboratory-based and Clinical Measures of Balance 
No studies were found that validate the use of any clinical or laboratory measures of 
postural control in any cancer population.  Additionally, no studies were found that use the 
single legged stance to measure postural control, a force plate was used to measure postural 
control in one study with a cancer population (Wampler et al., 2007).  Two studies were 
found that used the NeuroCom SOT in the breast cancer population (Wampler et al., 2007; 
Winters-Stone et al., 2011). 
Laboratory-based Measures of Balance. 
 The NeuroCom Sensory Organization Test (SOT) is used regularly in the assessment 
of balance in concussed athletes and other populations.  The NeuroCom Balance Master is an 
apparatus that consists of a moveable visual surround and a moveable force platform; the 
force platform and visual surround move in a sway-referenced fashion (“Sensory 
Organization Test,” 2011).  In cancer populations (specifically breast cancer), there have 
been a few studies using the SOT to assess balance.  Two studies used the SOT to assess 
balance in women with breast cancer; one assessed women that were treated with taxane 
therapy (Wampler et al., 2007)  and the other to assess fracture risk in post-menopausal 
breast cancer survivors (Winters-Stone et al., 2011).  In Wampler et al. (2007), twenty 
women treated with taxane chemotherapy for breast cancer with no central nervous system 
metastases were recruited; postural control was measured with a force plate and the SOT.  
SOT scores were lower in women with breast cancer when compared to controls in all 
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conditions except for quiet standing; women who were treated with taxane therapy showed 
poorer static and dynamic postural control.  Recently, Winters-Stone et al. (2011), assessed 
breast cancer survivors’ postural control with the SOT.  This study’s purpose was to evaluate 
fracture risk in breast cancer survivors (n=59).  The SOT was used to evaluate postural 
control; this study found that breast cancer survivors have decreased vestibular input, and 
those treated with chemotherapy only were 1.96 times more likely to have a fall (Winters-
Stone et al., 2011).  In addition to the SOT, force plates have been used to detect balance 
changes in clinical populations. 
 The use of a force plate to measure sway path and sway speed has been conducted in 
only one study to my knowledge (Wampler et al., 2007).  Wampler et al. (2007), found that 
women who were treated with taxane therapy had increased center of pressure velocities 
when compared to controls.  Force plates have also been used in populations with vestibular 
loss and peripheral neuropathy to identify balance deficits.  In a study of 12 patients with 
vestibular lesions and 2 without, it was found that under stable conditions, there was little 
difference between disordered patients and healthy ones.  When deprived of a stable support 
surface and visual input, patients with severe vestibular lesions performed more poorly on 
feet together balance tasks.  The authors concluded that vestibular input provides the 
orientation reference when conflicting visual and proprioceptive information are provided, 
and that when vestibular information is inhibited, decreases in balance occur (Nashner et al., 
1982).  In an other study, patients with vestibular loss swayed excessively or lost balance 
under conditions of inaccurate somatosensory information, accurate vestibular information, 
and either precluded or inaccurate visual information (Woollacott & Shumway-Cook, 1989).    
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 In patients with diabetic peripheral neuropathy, ample information is available 
regarding postural sway.  In a study of 50 patients with either diabetes (n=27) or bilateral 
cutaneous sensory deficit (n=23), patients with cutaneous deficit displayed increased postural 
instability when compared to the diabetes group.  These results indicated significant balance 
loss associated with cutaneous deficit (Simmons, Richardson, & Deutsch, 1997a).  In another 
study assessing static balance in patients with diabetic sensory neuropathy, 11 elderly 
patients with diabetic sensory neuropathy were age matched to healthy elderly controls; COP 
displacement was assessed with a force plate in the medial-lateral and anterior-posterior 
directions.  The COP displacement was significantly greater for diabetic peripheral 
neuropathy group in both the anterior-posterior and medial-lateral directions, indicating 
increased postural sway and increased instability in this population (Lafond et al., 2004). 
Clinical Measures.  
Most clinical measurements are based on visual judgment of steadiness.  Haupstein & 
Goldie (2000) validated the use of the single legged stance test (SLS) to determine postural 
stability.  A videotape of 20 five-second SLS balance performances were shown to 14 
experienced physiotherapists; intraclass correlations (ICC) were used to assess the reliability 
of the observers as well as the reliability of the test.  The intra-observer reliability was high 
(ICCaverage= 0.88) as well as inter-observer reliability (ICCtest1= 0.81, ICCtest2= 0.82).  Each 
physiotherapist watched the balance performances twice in order to determine inter-rater 
performance.  The errors of visual judgment were consistent across all groups, additionally 
the correlations between the visual judgments and steadiness measured by the force platform 
were found to be generally high (Haupstein & Goldie, 2000).  In a study by Buatois et al. 
(2006) SLS was compared to the SOT to determine fall risk.  No significant differences were 
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found between the non-fallers, the single-fallers, and the multi-fallers using the clinical SLS 
test.  However, the SOT produced statistically significant differences between the groups 
(Buatois, Gueguen, Gauchard, Benetos, & Perrin, 2006).  This finding supports the need for 
clinical use of sensitive measures of balance in clinical populations in which falls can be 
devastating.  
Implications of Decreased Balance Control on Quality of Life in Breast Cancer 
Survivors 
Poor balance is one of the major risk factors for falling (Choy, Brauer, & Nitz, 2003).  
In an elderly population, it is estimated that 1 in 3 people older than 65 years old will fall in a 
12-month period (Cho & Kamen, 1998; Lord, Clark, & Webster, 1991).  However, Winters-
Stone et al. (2011) found that a group of post-menopausal breast cancer survivors had higher 
rates of falling than the average fall rate for elderly community dwelling adults.  It has been 
shown that prevention of falls is easily obtained through interventions and training 
(Madureira et al., 2007).  Ensuring that a clinical assessment of balance is sensitive enough to 
detect disordered balance in a population is essential for developing interventions and 
preventing falls.  
Women who have been treated with chemotherapy, are on adjuvant endocrine therapy 
or are postmenopausal could have lower bone density.  Adjuvant hormonal therapy is used to 
block estrogen production in women with estrogen positive tumors, which can cause 
accelerated bone loss, which can lead to an increased risk of fracture.  Increased risk of falls 
and lower bone density can increase the risk of fracture among cancer survivors; this can 
decrease the quality of life of cancer survivors.  
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A study by Chen et al. (2005) compared bone density and the rate of change in bone 
mineral density (BMD) between 209 breast cancer survivors and 5759 non-cancer subjects.  
Using dual- energy x-ray absorptiometry (DEXA) scans on posterior-anterior spine, total hip, 
total body it was found that breast cancer survivors had a significantly higher prevalence rate 
of osteoporosis at the hip and total body, but not at the spine (Chen et al., 2005).  There was 
no difference in bone mineral density between the groups, but some subjects did not return 
for follow up measurements, which Chen admitted could have caused the discrepancy.  
Unlike Chen et al, Kanis et al. (1999) found that women with non-metastatic breast cancer 
had an increased risk of vertebral fracture.  Kanis’s study compared two groups of breast 
cancer patients (one group was first time diagnosis; the other was a second time diagnosis 
with soft tissue metastasis) with controls (n=1210).  They found that women with first time 
diagnosis were not significantly different in the prevalence of fractures when compared with 
the controls.  Conversely, women with soft tissue relapse were 6 times more likely to have a 
vertebral fracture (Kanis et al., 1999).  Women who had a diagnosis of breast cancer of any 
type also had a higher incidence of vertebral fracture than controls when followed after 
diagnosis, regardless of age.  Fractures were also more likely to occur in women with 
metastasis (Kanis et al., 1999). 
Women with endocrine sensitive tumors are often treated with endocrine therapy to 
suppress estrogen production.  Decreased estrogen can lead to amenorrhea and decreased 
bone density.  Winters-Stone et al. (2009) found that women with breast cancer had lower 
spine bone mineral density (BMD) than controls, as well as increased fall rate, decreased 
lower leg strength, and lower calcium intakes.  This study assessed 35 breast cancer survivors 
who had completed chemotherapy 6-12 months previously and were not on adjuvant 
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chemotherapy.  Bone mineral density of the greater trochanter, femoral neck, total hip and 
lumbar spine were assessed via DEXA.  Falls and fracture rates were collected via self-
report; there was no difference between the groups (control group n=28) in regards to BMD.  
Women who were taking adjuvant endocrine therapy had significantly lower BMD when 
compared to controls, and a higher percentage of women with breast cancer had a lower 
BMD when compared with controls (Winters-Stone, Nail, Bennett, & Schwartz, 2009). 
Adjuvant hormonal therapy is an important component of maintenance therapy for 
women with estrogen sensitive tumors.  Aromatase inhibitors (AI) block estrogen production 
and can cause bone loss (Mincey et al., 2006).  Mincey et al. (2006) studied 12,368 breast 
cancer patients with no bone metastases via an insurance billing claim database; of these 
patients 1,354 received AI therapy.  Using prevalence and incidence analysis, this study 
found that treatment with AI was associated with an increased risk for bone loss and bone 
fracture (incident rate of bone loss for treatment group and control groups =5.99 and 4.66 
respectively) (Mincey et al., 2006).  The AI group was also associated with a 1.35 fold 
increase in fracture risk (Mincey et al., 2006).  In another study involving AI therapy, 
Edwards et al. (2011) found an increased number of hip fractures among middle-aged 
women.  This study of 226 cases of fractures reveled that in women < 64 years there were 78 
hip fractures and 15 femur fractures associated with the use of AI (n=149) (Edwards et al., 
2011).  According to Winters-Stone et al. (2011), patients with cancer may have an increased 
risk of falling due to an accumulation of risk factors that they share with geriatric 
populations.  One study has been performed assessing fall incidence and fracture risk in 
female breast cancer survivors (Winters-Stone et al., 2011).  
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Using clinical tests that have been correlated with fall risk, Overcash and Rivera 
(2008) assessed fall risk in patients with cancer.  Twenty participants (age 68-83 years) with 
breast cancer, leukemia, lymphoma, blood disorders, and adenocarcinoma were assessed with 
the Timed Up and Go Test, fall questionnaires, and the Simmons Physical Test Performance 
Battery.  Thirteen subjects reported a fall within one year (n=13), within the past three 
months (n=15) and some subjects recalled falls since cancer diagnosis (n=12); only falls 
within one year correlated with the Timed Up & Go Test (Overcash & Rivera, 2008).  
These data indicate the need for fall risk assessment in cancer patients.  Balance 
assessment can help researchers and clinicians assess fall risk, decrease fracture risk, and 
allow for the patient to receive proper rehabilitative therapy. 
Conclusion 
Current literature is inconclusive about the issue of balance in the BCS population 
and points to the need to further examination of balance in the group.  Assessment of balance 
using clinical and laboratory based measures of balance will hopefully direct clinicians 
toward an easy and accurate way to assess for balance changes in the BCS population.  
 
	  	  
Chapter III 
Methodology 
Subjects 
This cross-sectional, descriptive study assessed balance in women who had been 
diagnosed with stages I-III (non-metastatic) breast cancer, undergone anti-cancer treatment 
(chemotherapy, surgery, radiation, or combination), and are currently taking maintenance 
hormonal therapy or chemotherapy.  Ten breast cancer survivors (BCS) who had been treated 
with chemotherapy and 10 age, weight, and pre-treatment physical activity level matched 
controls (CNT) enrolled to participate in this study.  In order to be eligible for this study, 
women with breast cancer must have been treated with chemotherapy during their major 
therapy and have completed their major therapy ≤ 6 months prior to recruitment.  Breast 
cancer survivors were recruited from The University of North Carolina at Chapel Hill (UNC-
CH), Get REAL and HEEL After Care Breast Cancer Research Program.  Controls were 
recruited via word of mouth.  To be included in this study, subjects may not have had chronic 
bone, joint or muscular abnormalities that compromised their ability to stand for a prolonged 
period of time.  Additionally for the BCS group, renal function with creatinine <1.5 mg/dL, 
immune deficiency that would compromise the patient’s health, absolute neutrophil count 
<1.5 uL of blood, platelet count test <90,000 per uL of blood, blood hematocrit <30%, or a 
diagnosis of metastatic disease would exclude participation from Get REAL and HEEL and 
from this study.  These criteria were determined through review of the physical activity 
readiness questionnaire (Par-Q), medical history questionnaire, and a complete blood count
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provided by an oncologist.  To be included as a control, subjects must have been: apparently 
healthy, sedentary women, with no history of chronic disease, between the ages of 25-75 
years, have no orthopedic problems that would limit the ability to stand unassisted, have no 
know vestibular problems, taking no medication that would cause balance disturbances, and 
must have been classified as “low risk” per American College of Sports Medicine guidelines 
(Thompson, Gordon, & Pescatello, 2010).  
This study employed the use of clinical and laboratory-based measures of balance.  
The clinical measure, the single legged stance (SLS), was based on time performance as 
determined by an observer and measured with a stopwatch in seconds to the nearest 
hundredth.  The laboratory-based measures included the measurement of sway speed and 
sway path during the SLS using the force plate.   
General Procedures 
Breast cancer survivors performed a series of fitness assessments as part of their 
initial evaluation in the Get REAL & HEEL Breast Cancer Research Program.  This initial 
series of fitness assessment included: body composition assessment, clinical assessment of 
balance, cardiovascular submaximal testing, upper and lower body muscular strength testing, 
and upper and lower body muscular endurance testing.  For this study, only the 
measurements of balance were used for analyses.  Strength and cardiovascular testing 
occurred after balance testing to eliminate any fatigue effects.  Controls only performed body 
composition measures and balance measures.  These measurements are discussed in detail in 
the next sections of Chapter III. 
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Instrumentation 
Prior to testing, all subjects underwent height and weight measurements on the 
Health-o-Meter 402KL (Rye, NY) stadiometer and physicians scale.  Advanced body 
composition analysis was performed by dual x-ray absorpometry (DEXA) for the BCS 
group.  For the timing of the clinical SLS, a stopwatch (Accusplit Survivor III, Model 
Magnum XL, Livermore CA) was used.  
A force plate (Bertec Model 40 60, Columbus, OH) was used to obtain ground 
reaction forces (Motion Monitor version 5, Chiacago, IL) during the SLS.  Custom LabView 
software (National Instruments 2011, San Antonio, TX) was used to evaluate sway path and 
sway speed.  The force plate sampled at 1000 Hz, each trial lasted 30 seconds.  A custom 
made electronic event trigger was used to mark each fall during the trials.  A fall was 
considered one of the following scenarios: if the knee touched the standing leg, if the non-
standing foot touched the ground, or if the eyes opened during an eyes-closed trial.   
Clinical and Laboratory-Based Balance Assessments  
Prior to balance testing, the BCS group underwent body composition analysis via the 
DEXA located in the Integrative Oncology Laboratory at UNC-Chapel Hill.  Balance testing 
was performed in the Neuromuscular Research Laboratory at UNC-Chapel Hill.  Prior to 
balance testing subjects were asked to determine leg dominance by stepping onto a raised 
platform 5 times; the leg that she stepped onto 3 out of 5 times was considered dominate.  
Balance testing was performed in ready position; ready position was described as: standing 
bare footed on a single leg on the force plate, with arms crossed across the chest, with head 
forward and eyes either open or closed (dependent upon the condition).  All subjects 
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performed balance testing on their dominant leg.  The researcher asked the subject to indicate 
their readiness with the phrase “Ok, Go”.   
The single leg stance was performed on the right leg, under two conditions (eyes open 
and eyes closed), with three trials per condition, totaling six 30-second tests.  Between trails 
there was a short recovery, lasting no more than 30 seconds.  The clinical portion of the test 
was terminated at the loss of balance or a fall in any direction.  The clinical test was timed 
and measured to the nearest hundredth of a second.  Timing of the clinical portion started as 
soon as the subject indicated readiness; timing ended at a loss of balance or at 30 seconds.  
During the eyes closed trials, timing began once the subject closed her eyes and then 
indicated readiness.  If a subject was unable to achieve the SLS, the time was recorded as 
0.00 seconds.  The visual judgment assessment of the one-legged stance was validated by 
Haupstien and Goldie (2000).  There were three trials with eyes open and eyes closed; the 
mean times were recorded as the test times and used for analysis.  
The timing of the clinical SLS occurred simultaneously with the sampling of the sway 
path and sway speed data from the force plate.  When the subject indicated readiness, the 
electronic trigger was used to begin data collection with the force plate.  The electronic 
trigger was also used to mark any falls during the 30-second sampling time.  The trigger 
enables the researcher to remove data in which a fall has occurred and the subject was 
regaining her balance.  After a fall was recorded, the subject was able to regain the ready 
position and the laboratory-based test continued.  The laboratory-based test ended after the 
30 seconds; whereas, the clinical test ended after the first fall.   For the clinical and the 
laboratory based tests, the definition of a fall was the same.  The clinical tested ended after 
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the first fall, the laboratory based test continued for 30 seconds, and the trigger was used to 
mark all falls during that time.  
Data Reduction 
 Analog data from the force plate were sampled at 1000 Hz, during each 30-second 
trial.  Custom LabView software (National Instruments 2011, San Antonio, TX) was created 
to analyze the ground reaction forces.  Ground reaction forces were filtered through a fourth 
order, low pass, Butterworth filter with a cutoff frequency of 10 Hz.  Ground reaction forces 
were used to calculate center of pressure coordinates, which were then used to determine 
sway speed (cm/sec) and sway path (cm).   Sway speed were calculated using the average 
distance the subject swayed over the three trials, divided by the average number of seconds 
the single leg stance was performed over the three trials.  Similarly, sway path was calculated 
using the average distance the subject travel during the SLS.  
Statistical Analyses 
All data analysis were performed on SPSS Version 19 (Armonk, New York).   
Descriptive statistics were presented in form of means and standard deviations.  A Bonferroni 
adjustment was performed to minimize the possibility of Type I error occurrence, since 
multiple dependent t-tests were performed on the same data set.  The p-values for the 
analyses were set a-priori at < 0.05.  Dependent t-tests were chosen due to the homogeneity 
of the CNT to the BCS.  Due to the small sample size, the effect size was computed (Cohen, 
1988).  Effect size is defined as: “small, d=0.2”, “medium, d= 0.5”, and “large, d= 0.8”  
(Cohen, 1988).   
 
	  	   32	  
Hypotheses 
H1.  There will be no significant difference in the number of seconds that the clinical SLS is 
performed between BCS and CNT with eyes open.  A dependent t-test will be used to 
compare the differences in the number of seconds the BCS and CNT groups can perform the 
SLS with eyes open  
H2.  There will be no significant difference in the number of seconds that the clinical SLS is 
performed between BCS and CNT with eyes closed.  A dependent t-test will be used to 
compare the differences in the number of seconds the BCS and CNT can perform the SLS 
with eyes closed.  
H3.  The BCS group will have a faster sway speed (cm/s) when measured using the force 
plate compared to the CNT group when SLS is performed with eyes open. A dependent t-test 
will be used to compare the differences sway speed between the BCS and CNT groups 
during the SLS with eyes open.  
H4. The BCS group will have a faster sway speed (cm/s) when measured using the force 
plate compared to the CNT group when SLS is performed with eyes closed. A dependent t-
test will be used to compare the differences sway speed between the BCS and CNT groups 
during the SLS with eyes closed.  
H5. The CNT group will have a smaller sway path when compared to the BCS group during 
the single leg stance with eyes open when the sway path is measured in centimeters through 
the force plate. A dependent t-test will be used to compare the differences sway path between 
the BCS and CNT groups during the SLS with eyes open.  
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H6. The CNT group will have a smaller sway path when compared to the BCS group during 
the single leg stance with eyes closed when the sway path is measured in centimeters through 
the force plate.  A dependent t-test will be used to compare the differences sway path 
between the BCS and CNT groups during the SLS with eyes closed.  
 
	  	  
Chapter IV 
Results 
 The purpose of this study was to compare clinical and laboratory-based measures of 
balance between early stage breast cancer survivors and apparently healthy, sedentary, and 
age-matched controls.  All data were analyzed using SPSS version 19 (Armonk, NY); a p 
value of 0.05 was set a priori and was used for all statistical procedures.  Descriptive 
statistics were presented in the form of means and standard deviations.   
Subjects 
 Twenty female subjects, 10 BCS who have recently completed treatment within 6 
months, and 10 age, weight, and physical activity level matched CNT, were recruited and 
tested at UNC-CH in the Neuromuscular Research Laboratory.  The treatment characteristics 
of the BCS group are presented below in Table 2.  
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Table 2. Breast Cancer Group Treatment Characteristics 
 
 
Cancer 
Stage Chemotherapeutic 
Radiation 
(yes/no) Adjuvant Therapy 
Finished 
Treatment 
BCS 01 II 
Cytoxan, 
Adriamycin, 
Taxotere,  yes Tamoxifen 12/2011 
BCS 02 III AC*/Taxol yes Herceptin, Femara 6/2011 
BCS 03 III Cytotoxan/Taxol yes 
Herceptin, Xeloda, 
Tykerb, Tamoxifen 8/2011 
BCS 04 III AC/Taxol yes Tamoxifen 1/2012 
BCS 05 II AC/Taxol no Tamoxifen 2/2012 
BCS 06 I AC/Taxol yes Tamoxifen 2/2012 
BCS 07 II AC/Taxol yes Tamoxifen 12/2011 
BCS 08 I Taxotere  yes n/a 9/2011  
BCS 09 III Taxol/AC yes Herceptin/ Femra 9/2011 
BCS 10 III Taxol/Herceptin yes 
Herceptin/Zometa/ 
Arimidex 9/2011 
Twenty percent of the BCS group was treated for stage I breast cancer, 30% was treated for 
stage II, and 50% was treated for stage III.  All members of the BCS group received Taxol or 
a Taxane derivate and all but one subject received radiation as part of their major treatment.  
Sixty percent of the BCS group was taking Tamoxifen as part of their adjuvant therapy, 
during the study 40% were taking Herceptin, and one was not undergoing an adjuvant 
therapy.  Sixty percent of all subjects were at least 6 months post completion of their major 
cancer treatments while the other 40% were within 3 months, the average time off therapy 
was 4.2 months.  Subject characteristics are presented below in Table 3. 
Table 3. Descriptive Statistics presented as mean ± standard deviations (SD) for all 
study participants (n= 20)  
  BCS (Mean ± SD) CNT (Mean  ± SD) 
Age (Years) 51.9 ± 7.7  51.2 ± 10.6  
Height (cm) 153.4 ± 11. 6 154 .0 ± 11.8 
Mass (kg) 77.7 ± 14. 5 69.4 ± 11. 3  
No differences between groups were observed for age, height and weight (p=0.73, p ≥ 0.99, 
p=0.69, respectively).   
	  	   36	  
H1.  There will be no significant difference in the number of seconds that the clinical single 
leg stance is performed between BCS and CNT with eyes open.  A dependent sample t-test 
was used to analyze average number of seconds that the single leg stance was performed with 
eyes open between the BCS and CNT groups.  No significant difference was observed  
(26.15 ± 2.87 sec, 22.09 ± 2.83 sec, respectively; p= 0.19).  The Cohen’s D for effect size for 
the paired samples t-test was small (ES=0.2).  
H2.  There will be no significant difference in the number of seconds that the clinical single 
leg stance is performed between BCS and CNT with eyes closed.  A dependent sample t-test 
was used to analyze average number of seconds that the single leg stance was performed with 
eyes open between the BCS and CNT groups. No significant difference between groups was 
observed (5.58 ± 3.95 sec, 3.90 ± 3.07 sec, respectively; p= 0.18).  The Cohen’s D for effect 
size for the paired samples t-test was small (ES=0.3).  
H3.  The CNT group will have a slower sway speed when compared to the BCS group with 
eyes open during the single leg stance when sway speed is measured in centimeters/second 
(cm/s) through the force plate.   A dependent sample t-test was used to analyze average sway 
speed with eyes open between the BCS and CNT groups.  No significant difference between 
groups was observed (4.50 ± 1.44 cm/sec, 4.24 ± 1.28 cm/sec, respectively; p= 0.35).  The 
Cohen’s D for effect size for the paired samples t-test was small (ES=0.1).  
H4. The CNT group will have a slower sway speed when compared to the BCS group with 
eyes closed during the single leg stance when sway speed is measured in centimeters/second 
(cm/s) through the force plate.  A dependent sample t-test was used to analyze the average 
sway speed with eyes closed between the BCS and CNT groups.  No significant difference 
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between groups was observed (11.72 ± 4.59 cm/sec, 10.74 ± 3.18 cm/sec, respectively; p= 
0.27).  The Cohen’s D for effect size for the paired samples t-test was small (ES=0.2).  
H5. The CNT group will have a smaller sway path when compared to the BCS group during 
the single leg stance with eyes open when the sway path is measured in centimeters through 
the force plate.  A dependent sample t-test was used to analyze the average sway path 
between the BCS and CNT groups.  No significant difference between groups was observed 
(127.91 ± 35.86 cm, 111.24 ± 27.91 cm, respectively; p= 0.17).   The Cohen’s D for effect 
size for the paired samples t-test was small (ES=0.3).  
H6. The CNT group will have a smaller sway path when compared to the BCS group during 
the single leg stance with eyes closed when the center of pressure is measured in centimeters 
through the force plate.  A dependent sample t-test was used to analyze the average sway 
path between the BCS and CNT groups.  No significant difference between groups was 
observed (228.04 ± 69.80 cm, 218.93 ± 55.78 cm, respectively; p= 0.37).  The Cohen’s D for 
effect size for the paired samples t-test was small (ES=0.1).  
 
 
 
 
 
 
 
 
 
	  	  
Chapter V 
Discussion, Conclusion and Recommendations  
  To date, there are 12.5 million cancer survivors in the United States, 2.5 million of 
those are breast cancer survivors ("What is breast cancer?", 2012).  Survivors of breast 
cancer are often left dealing with a wide array of side effects from their treatment.  Many of 
these are well studied; however some, such as balance, are understudied and information 
regarding this potentially long term issue is still developing.  Two studies have been 
published regarding breast cancer and balance (Wampler et al., 2007; Winters-Stone et al., 
2011).  These studies indicate that decreased balance in breast cancer survivors is an 
important issue and can put breast cancer survivors at increased fall risk.  One unpublished 
thesis out of The Department of Exercise and Sport Science at UNC-CH indicated that there 
was no difference between breast cancer survivors and healthy controls in regards to balance 
(Tysinger, 2010).  The field of balance for cancer survivors is still developing and these are 
important findings that require further study and consideration.   
 Balance decline in healthy populations is well established as a normal process that 
occurs with aging (Choy et al., 2003; Toledo & Barela, 2010).  The sensory systems that are 
required for balance often undergo age related denegation (Nardone et al., 2007; Rauch et al., 
2001).  However, the published research shows that balance decline is occurring in 
nonelderly breast cancer survivors (Wampler et al., 2007; Winters-Stone et al., 2011).  
Possible causes of this decline have been attributed to treatment related side effects such as 
peripheral neuropathy or vestibular damage.  In non-cancer populations, it is has been found
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that peripheral neuropathy, has been related to balance decline in other populations in 
addition to the breast cancer population (Simmons et al., 1997b; van Deursen & Simoneau, 
1999; Wampler et al., 2007).  Additionally, damage to the vestibular organ has been known 
to cause balance changes in those treated with chemotherapeutics and those with external 
damage (Gabriele, Orecchia, Magnano, Albera, & Sannazzari, 1992; Sergi et al., 2003).   
 Balance changes in the breast cancer population are of great concern due to reports of 
low bone density, fall risk, and quality of life issues (Holley, 2002; Stone, Lawlor, & Kenny, 
2011; Winters-Stone et al., 2009).  Therefore, the purpose of the present study was to 
compare clinical and laboratory-based measures of balance between early stage breast cancer 
survivors and apparently healthy, sedentary age-matched controls.   
Clinical Test for the Assessment of Balance in Breast Cancer Survivors  
The single leg stance  (SLS) was used to measure static measure balance in breast 
cancer survivors (BCS) and healthy, age, weight, and physical activity level matched controls 
(CNT).  No significant difference was found between the two groups when SLS was 
measured in seconds during the eyes open trials (p=0.19).  The BCS group was able to 
maintain their SLS for an average of 26.15 ± 2.87 seconds as compared to the CNT group, 
which was able to maintain their SLS for 22.09 ± 2.83 seconds.  The eyes open trials for the 
BCS and CNT groups were both below reported normative values (30.0 ± 0.0 seconds) 
(Vereeck, Wuyts, Truijen, & Van de Heyning, 2008).   The current study also found no 
significant difference between groups during the SLS with eyes closed.  The mean values of 
5.58 ± 3.95 seconds and 3.90 ± 3.07 seconds for the BCS group and CNT group are also both 
below the normative time reported (8.9 ± 7.5 sec).  The normative values for the SLS are 
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based on healthy adults; the fact that the BCS and CNT groups both performed below the 
normative values during this study indicate that the both groups may have had compromised 
balance.  This could be part of the reason for the finding that there was no significant 
difference between the CNT and BCS groups in the present study.   
Even though no statistically significant difference between groups was found, it was 
somewhat unanticipated that the BCS group would be able to maintain the SLS, in both, eyes 
open and eyes closed trials for slightly longer duration than the CNT group.  The non-
significant difference between groups for the SLS is in agreement with the only previous 
study conducted to date that compared static balance using the SLS measured in seconds 
(Tysinger, 2010).  Interestingly, the BCS group in the current study was able to maintain the 
SLS longer than the BCS group from Tysinger (2010) (5.58 ± 3.95; 4.81 ± 3.28 sec 
respectively).  Some potential explanations for the improved performance of the current BCS 
group’s could be related to the number of subjects in the current study, which are also 
indicated by the effect size calculations.  Tysinger (2010) had 40 BCS who were slightly 
older than the current study’s BCS group (53.48 ± 9.73; 51.9 ± 7.75 yrs, respectively).  This 
larger sample size and increased age of the cancer survivors sampled could have decreased 
the average number of seconds that the BCS was able to perform the SLS in Tysinger (2010).  
A potential reason for the differences between studies may be attributed to the fact 
that in the current study, data were reported for only one leg during the SLS.  In Tysinger 
(2010), the SLS was performed on the subject’s self selected leg; differences between legs 
were not reported.  In the current study, ground reaction force values for the right leg and the 
clinical SLS were performed using only the right leg due to technical difficulties with the 
force plate.  Therefore, regardless of subject’s comfort or clinical performance on the SLS, 
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data were used from the right leg in the current study.  However, several studies have 
reported no difference in the evaluation of SLS between limbs (Dietz, Horstmann, & Berger, 
1989; Geurts, Nienhuis, & Mulder, 1993; Goldie, Bach, & Evans, 1989).  The current study 
recorded time (sec) data for the clinical SLS on both legs.  The results are presented in 
comparison to Tysinger (2010) below in Table 4. 
Table 4. Differences Between the Current Study and a Similar Study Assessing Balance 
Using the SLS Measured in Seconds.  
Trial/Study Mean Time ± Standard Deviation 
Current Study- Eyes Closed Right Leg 5.58 ± 3.96 
Current Study- Eyes Closed Left Leg 6.33± 4.87 
Tsyinger et al.  (2010) 4.81± 3.28 
On average, subjects in the current study were able to perform the SLS longer than subjects 
in previously conducted studies  
As previously mentioned, the results of the current study are in agreement with 
Tysinger (2010).  In the aforementioned study, 40 BCS and 25 CNT, matched on weight, 
height and age showed no statistically significant difference when the SLS was measured in 
seconds. However when dynamic balance was assessed using the foursquare step test, the 
BCS and CNT groups did differ significantly (p=0.08); the BCS group performed better than 
the CNT group (Tysinger, 2010).  This was attributed to increased concentration of the BCS 
group during the dynamic tests according to the authors (Tysinger, 2010).  
In Tysinger (2010), all of the subjects received some form of treatment, not all 
received the same type of treatment, and in fact not all subjects had chemotherapy.  The BCS 
that had chemotherapy were treated with a wide variety of types (Tysinger, 2010).  The 
sample in the current study, even though smaller, was much more homogenous regarding 
treatment.  It is possible that the treatment that the current study’s BCS group received 
allowed for better performance on the clinical SLS.  Tysigner (2010) did not report the 
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average time off therapy or the current adjuvant therapy for their sample, the improved 
performance of the current study’s BCS group could be related to the time off therapy or to 
the adjuvant therapy type.  It is possible that for the current study, the time off therapy has 
been long enough to cause adaptation or diminish the effect of treatment; however, further 
research is needed to confirm this.   
As an attempt to explain the non-significant difference between BCS and CNT for the 
SLS, exploratory analysis using the Sensory Organization Test (SOT) was examined. The 
results of the SOT analyses are presented below in Table 5. 
Table 5. SOT Results Between CNT and BCS  
 
CNT Mean ± SD BCS Mean ± SD p value 
Effect 
Size 
Composite Score 78.75 ± 6.01 73.75 ± 10.33 0.19 - 
Vestibular Ratio 0.72 ± 0.10 0.65 ± 0.15 0.27 0.4 
Visual Ratio 0.88 ± 0.04 0.90 ± 0.05 0.53 0.2 
Somatosensory Ratio 0.97 ± 0.01 0.95 ± 0.02 0.17 0.5 
Preferential Ratio 0.95 ± 0.10 0.88 ± 0.13 0.13 - 
Dependent sample t-tests were used for the analyses. No significant difference between 
groups was observed for any component of the SOT test.  The effect sizes indicate that more 
subjects are needed.  
These results are unlike those of Wampler et al. (2007) and Winters-Stone et al. 
(2011) who found that breast cancer survivors had deficits during the SOT that were reflected 
in their vestibular ratios when compared to matched controls; meaning a vestibular 
integration problem in breast cancer survivors may exist.  The lack of a statically significant 
difference between the BCS and CNT groups in this study could be an issue of being 
underpowered; it appears that the vestibular ratio provided by the SOT may be clinically 
different, however more research is needed to confirm this.   
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The BCS group in this study were highly functional; most were working either part or 
full time, and it appeared that they were trying to maintain a normal lifestyle despite being a 
breast cancer survivor.  Many of the members of the BCS group anecdotally expressed 
excitement regarding the start of the rehabilitation at Get Real and Heel.  Wampler et al. 
(2007) and Winters-Stone et al. (2011) did not report on the physical activity level of their 
cohorts in addition to the lifestyle characteristics of their BCS groups.  The CNT in this study 
were verbally asked about their physical activity level.  If they indicated that they were 
performing regular physical activity (at least 3 days a week for at least 30 minutes), they 
were not eligible to participate; however, there was no objective measure of physical activity 
level in this study.  The increased functionality and increased desire to perform well could 
have enabled the BCS group in the current study to out perform the CNT group during the 
balance testing, and could, in part, be the reason for the discrepancies between this study and 
the only other two published studies to date (Wampler et al., 2007; Winters-Stone et al., 
2011).   
Winters-Stone et al. (2011) used the SOT to assess fall risk in 59 breast cancer 
survivors.  They divided their BCS group into a positive fall history group (n=34) and a 
negative fall history group (n=25); on average, both groups were older than the current 
study’s BCS group (59.2± 7.1, 57.4 ± 12.4, 51.90 ± 7.79 yr; respectively).  Due to the 
difference in age, it is possible that there is an age related difference in the SOT performance 
between the current study’s BCS group and Winters-Stone et al. (2011).  Winters-Stone et al. 
(2011) hypothesized that the increased fall risk their BCS group may be related to alterations 
of vestibular inputs (Rosenhall & Rubin, 1975; Winters-Stone et al., 2011).  
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In summary, no significant differences between BCS and CNT groups for the SLS 
using seconds was observed.  The results of the exploratory analyses using the SOT support 
the current findings, since no statistically significant difference between BCS and CNT was 
observed for any component evaluated by the SOT.  The younger age and the highly 
motivated group of patients who participated in the study along the sedentary nature of the 
control subjects may explain in part the non-significant difference between groups.  The 
effect size calculations small for the SLS t-tests, and medium for the SOT t-tests, this 
indicates that Lastly, due to the small sample size, which could potentially impact the results 
of the current study, it is recommended that future trials reproduce the current study with a 
larger sample.  
Laboratory-based Measures of Balance in Breast Cancer Survivors  
 In this study, no difference was found between the BCS and CNT groups using the 
force plate.  The results of the current study do not agree with previous studies that also 
evaluated balance in BCS using laboratory-based tests (Wampler et al. 2007; Winter-Stone 
el. al 2011). Similarly to Wampler et al. (2007), sway speed (cm/sec) and sway path (cm) 
were evaluated using the force plate.  However, Wampler et al. (2007) found differences in 
the sway path and sway velocity (speed) between her BCS and CNT groups (p ≤ .0125).  The 
different results observed between the current and Wampler et al. (2007) studies, could be 
attributed to the different way Wampler et al. (2007) used to assess sway speed and sway 
path.  In Wampler et al. (2007), center of pressure (COP) variables were assessed through a 
battery of static balance tests where the head was in varying positions and the eyes were 
either open or closed; the subjects were tested standing on both feet (Wampler et al., 2007). 
The greatest differences were in the trials in which vision was occluded or vestibular 
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information was altered (Wampler et al., 2007).  Another potential explanation for the 
discrepancy in results between the current study and Wampler et al. (2007) may be attributed 
to the fact that the 20 BCS in Wampler’s study were only within 30 days of their final taxane 
infusion.  It is possible that since our BCS group was farther off therapy (4.0 ± 2.6 mo) that 
the treatment related effects had either caused adaptation when static balance was measured, 
or did not affect static balance.  
 Our sample was younger than Winters-Stone et al. (2011) (58.5±9.7 yr), and about 
the same age as Wampler et al. (2007) (50.35±9.34 yr).   Additionally, our sample was 
smaller in stature than Wampler et al. (2007) (153.47 ± 11.60, 165.15 ±5.57 cm; 
respectively).  It is possible that these differences in height and age caused differences in the 
performance on SLS when measured by the force plate.  The findings of the current study 
indicate that the balance issues that are anecdotally reported by female survivors of breast 
cancer could be related to dynamic balance regulation instead of static balance, the time off 
treatment, or the sedentary nature of BCS.  
The other studies that have been conducted support this finding (Tysinger, 2010; 
Wampler et al., 2007; Winters-Stone et al., 2011).  Published studies assessing balance in 
BCS have found that the information from the vestibular system is deregulated (Wampler et 
al., 2007; Winters-Stone et al., 2011); the vestibular system plays a critical role in dynamic 
balance regulation (Marieb & Hoehn, 2007). 
 Exploratory analysis using the biothesiometer showed that the BCS group had an 
increased vibration threshold compared to the CNT group.  Vibration threshold has been used 
as an important indicator of peripheral neuropathy as a part of the modified total neuropathy 
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score (mTNS).  The mTNS is used in many clinical populations to evaluate severity of 
neuropathy and has been validated for use in identifying taxane and platinum induced 
neuropathy in breast cancer survivors (E. M. Smith, Cohen, Pett, & Beck, 2010; Wampler, 
2006).  The mTNS is a seven measure assessment, one of these measures is vibration 
threshold (E. M. Smith et al., 2010).   Recently, Wampler et al. (2007) used the mTNS as part 
of their study on balance deficits in breast cancer survivors.  Wampler et al. (2007) reported 
that their BCS group performed more poorly on the mTNS than the controls.  In the current 
study, vibration thresholds of the hallux joint on both feet between the BCS and CNT groups 
were evaluated.  The results of the analyses using the Biothesiometer are presented below in 
Table 6.   
 Table 6. Vibration Threshold Analyses Between BCS and CNT Groups 
 
CNT Mean ± SD BCS Mean ± SD p value 
Right Ascending (V) 10.16 ± 2.32 19.43 ± 11.34 0.03 
Right Descending (V) 11.50 ± 3.75 17.73 ± 7.64 0.05 
Left Ascending (V) 11.53 ± 4.22 16.86 ± 8.26 0.07 
Left Descending (V) 12.56 ± 6.31 17.20 ± 6.53 0.11 
On average, the BCS group had a higher vibration threshold when compared to the CNT 
group.  
 Although the ascending trial on the right foot was the only trial that held statistical 
significance, it is apparent that the BCS group had an increased vibration threshold based on 
the means of the trials.  This indicates that the BCS group had decreased sensation when 
compared to CNT in their feet.  In addition to having an increased threshold when compared 
to the controls in this study, the BCS group also was above the normative value for vibration 
threshold for their age group (12.1 V) (Bloom, Till, Sönksen, & Smith, 1984).  This supports 
the speculation that the time off treatment of approximately 3-6 months may be enough for 
patients to return to their prior treatment ability to control balance. This is all speculative and 
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further research is needed to confirm or refute this supposition.   In addition to further 
research regarding neuropathy, further analysis using electromyography should be performed 
to assess muscle activation in conjunction with peripheral neuropathy.   
 In summary, no statistically significant differences between the BCS and CNT groups 
for the SLS using the force plate were observed.  Exploratory analysis using the 
biothesiometer indicated some differences in the vibration thresholds of the BSC group when 
compared to the CNT group, however the majority of these were also not statistically 
significant.  The younger age and high level of physical function of the BCS group could be a 
possible explanation of the differences between studies.  The small sample size could have 
potentially impacted the results of the current study; therefore, it is recommended that this 
study be repeated with a larger sample size.  
There were some limitations to the current study: This study reported SLS data on 
only one leg (right leg).  Even though data support no difference between sides during the 
SLS (Dietz et al., 1989; Geurts et al., 1993; Goldie et al., 1989), there could have been an 
unknown difference in this specific population.  Additionally, there was a large variation of 
the time off therapy in the study group.  This could have caused a wide variation in the data 
set regarding treatment related side effects that could negatively affect balance.   A small 
sample size could have additionally affected the current study’s results and further research is 
needed to confirm the findings of this study.  To validate the severity and presence of 
peripheral neuropathy, it would have been beneficial to collect data specifically on the 
presence of peripheral neuropathy to use in conjunction with the information from the 
biothesiometer.  
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Conclusion 
No significant differences in static balance using either clinical or laboratory-based 
tests for the assessment of static balance in BCS were observed in this study.  It appears that 
for the younger population of BCS enrolled in this study, the different amount of time off 
anti-cancer treatment, and the smaller sample size when compared to previous studies, 
explain in part the different findings of the current study when compared to previous studies.  
Nevertheless, the results of the current study suggests that younger BCS who have completed 
their major cancer treatment within 6 months did not experience compromised ability to 
control their balance statically with the measure of SLS using a clinical and laboratory based 
measure.  Perhaps the anecdotally reported balance issues by BCS may be associated with 
tasks that involve dynamic balance, or perhaps are cognitive issues believed to impact this 
population during and after completion of treatment or the lack of statsically signficant 
findings were related to the realtively small sample size.  Repeating this study with an 
increased sample size is reccomended in order to confirm or refute the findings of this study.   
Recommendations for future study  
From the results of this study, below are the recommendations for future study.   
1. Use dynamic assessments of balance in addition to static assessments of balance.   
2. Perform studies on homogenous groups of BCS.  For example, it would be beneficial 
to preform static and dynamic balance testing on BCS that had taxane and compare 
them to BCS that did not have taxane.  
3. Collect data specific to chemotherapy induced peripheral neuropathy in order to 
assess the role that CIPN has on balance in breast cancer survivors.  
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4. Compare balance in BCS over multiple age groups would be beneficial to see age 
effects on BCS 
5. Include other measurements to validate exploratory analysis, such as 
electromyography.  
6. Measure balance in BCS at different time points after treatment. 
7. Physical activity may influence balance; therefore, objective measurements of 
physical activity level should be included during study recruitment.   
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